Search Results
354 results
Your search is now limited to «Ovarian Cancer» expert search.
MedPageToday.com 03/20/2019 16:30
Herzog explained that the staged approach is predicated on the fact that the fallopian tube is the genesis for most ovarian serous cancers and that endogenous estrogens improve women's quality of life (QOL), and perhaps even survival.
More from MedPageToday.com:
Targeted Oncology 03/20/2019 12:15
In the international, open-label, multicenter, JAVELIN Ovarian PARP 100 trial, investigators randomized treatment-naïve patients with locally advanced or metastatic ovarian cancer to receive avelumab in combination with chemotherapy followed by maintenance avelumab in combination with talazoparib versus an active comparator.
More from Targeted Oncology:
Zacks.com 03/20/2019 11:30
First, the degree of benefit observed with avelumab in frontline ovarian cancer in the JAVELIN Ovarian 100 study did not support continuation of the JAVELIN Ovarian PARP 100 study, the companies said or for that matter evaluating an immunotherapy in ovarian cancer itself.
More from Zacks.com:
Healio News 03/20/2019 08:00
Cibula and colleagues enrolled 71 women with serous, endometrioid or mucinous ovarian carcinoma from 15 centers in Europe between November 2013 and May 2015.
More from Healio News:
Medindia.com 03/20/2019 07:28
New class of drugs could kill ovarian cancer cells, providing a potential new treatment option for ovarian cancer, according to the University of Manchester researchers.
More from Medindia.com:
Health Europa 03/20/2019 07:16
Causing more than 4,000 deaths each year These findings are promising for patients diagnosed with ovarian cancer, which is the sixth most common cause of cancer in women in the UK and causes more than 4,000 deaths each year.
More from Health Europa:
WN.com 03/20/2019 06:41
DARMSTADT, Germany and NEW YORK, March 20, 2019 /PRNewswire/ -- Merck and Pfizer Inc. (NYSE: PFE) today announced the discontinuation of the ongoing Phase III JAVELIN Ovarian PARP 100 study evaluating the efficacy and safety of avelumab in combination with chemotherapy followed by maintenance therapy of avelumab in combination with talazoparib,* a poly (ADP-ribose) polymerase (PARP) inhibitor, versus an active comparator in treatment-naïve patients with locally advanced or metastatic ovarian cancer (Stage III or Stage IV).
More from WN.com:
PharmaTimes 03/20/2019 06:29
The degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasises the need to better understand the role of immunotherapy in ovarian cancer.
More from PharmaTimes:
Pharmafile 03/20/2019 06:07
The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer.
More from Pharmafile:
PubMed News (NIH) 03/20/2019
Series Type : Expression profiling by array ; Non-coding RNA profiling by array Organism : Homo sapiens ; synthetic construct. This SuperSeries is composed of the SubSeries listed below.
More from PubMed News (NIH):
Cancer Network 03/20/2019
A phase III trial to further evaluate dendritic cell–based immunotherapy in combination with chemotherapy for recurrent ovarian cancer is planned for 2019.
More from Cancer Network:
Cancer Cell International 03/19/2019 20:00
Cell culture All the ovarian cancer cell lines used in the study were primarily obtained from American Type Culture Collection (ATCC, Manassas, VA, USA.
More from Cancer Cell International:
PR Newswire 03/19/2019 19:15
The alliance determined that the degree of benefit observed with avelumab in frontline ovarian cancer in that study does not support continuation of the JAVELIN Ovarian PARP 100 trial in an unselected patient population and emphasizes the need to better understand the role of immunotherapy in ovarian cancer.
More from PR Newswire:
Business Wire 03/19/2019 16:00
In the randomized, open label SOV02 clinical trial, patients with recurrent ovarian cancer received DCVAC/OvCa in combination with platinum-based chemotherapy.
More from Business Wire:
ClinicalTrials.gov 03/19/2019 09:24
Condition : Ovarian Cancer Intervention : Diagnostic Test: HRD and BRCA mutations Sponsor : Institut de Cancérologie de Lorraine Not yet recruiting.
More from ClinicalTrials.gov:
Why ovarian cancer is called a 'silent killer' About 80 percent of ovarian cancer cases are diagnosed in the advanced stages of the disease.
More from Mail on Sunday (United Kingdom):
GlobeNewswire 03/19/2019 07:05
These data come from a retrospective ex vivo analysis of 40 tumor and serum samples collected pre- and post-neoadjuvant chemotherapy in ovarian cancer patients using Aravive’s GAS6 biomarker assay.
More from GlobeNewswire:

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors

Cells

Diagnostics and Therapeutics

Diseases

Drugs - Brand Names

Drugs - Generic

Enzymes

Genes

Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices

Proteins

Sources

Strategic Scenarios

Trends

Hints:

On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 


  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications